Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 3 |
2020 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4.
Clin Cancer Res. 2020.
PMID: 31585938
Free PMC article.
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.
Facchinetti F, Hollebecque A, Bahleda R, Loriot Y, Olaussen KA, Massard C, Friboulet L.
Facchinetti F, et al.
Clin Cancer Res. 2020 Feb 15;26(4):764-774. doi: 10.1158/1078-0432.CCR-19-2035. Epub 2019 Oct 4.
Clin Cancer Res. 2020.
PMID: 31585937
Free PMC article.
Review.
Item in Clipboard
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R.
Gong B, et al.
J Exp Med. 2019 Apr 1;216(4):982-1000. doi: 10.1084/jem.20180870. Epub 2019 Mar 14.
J Exp Med. 2019.
PMID: 30872362
Free PMC article.
Item in Clipboard
Cite
Cite